Company Profile

Acasti Pharma is a biopharmaceutical innovator that has historically focused on advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk. Acasti conducted two Phase 3 clinical trials: the TRILOGY trials. In TRILOGY 1, CaPre® achieved a 30.5% reduction in triglyceride levels at 12 weeks and 36.7% reduction in triglyceride levels at 26 weeks, as well as 42.2% reduction in triglyceride levels among patients receiving CaPre while on background statin therapy at 12 weeks. Despite positive results in the CaPre arm, the TRILOGY 1 study did not reach statistical significance. In TRILOGY 2, CaPre achieved 30.4% median reduction in triglycerides at 12 weeks and 38.4% at 26 weeks, but did not achieve statistical significance for the primary endpoint.

Latest Presentation

Industry Classifications

Sector:
Health

Industry:
Biotechnology

NAICS:
Pharmaceutical Preparation Manufacturing (325412)

SIC:
Pharmaceutical and Medicine Industry (3741)

Contact Information

Investor Relations
Crescendo Communications, LLC
Chrysler Building
405 Lexington Ave
9th Floor, Suite 9034
New York, NY 10174
T: 212-671-1020
ACST@crescendo-ir.com

Company Contact
Acasti Pharma Inc.
3009 Boul. de la Concorde E.
Suite 102
Laval, Québec H7E 2B5
Canada